Italy Formally Submits Detailed Opinion to EU Obstructing Ireland's Disposable Vape Ban

Apr.10
Italy's Ministry of Enterprises and Made in Italy has submitted a detailed opinion against Ireland's proposed "Public Health (Single Use Vapes) Bill 2025." Italy argued that the comprehensive ban on disposable vapes lacks scientific evidence, violates the EU principle of the free movement of goods, and conflicts with the existing Tobacco Products Directive.

Key Takeaways

  •  According to a European Commission document, the standstill period for Ireland's bill banning disposable vapes has been formally extended to June 19, 2026.
  • Italy's Ministry of Enterprises and Made in Italy submitted a detailed opinion to the EU on March 19, 2026, opposing Ireland's "Public Health (Single Use Vapes) Bill 2025."
  • The Irish bill intends to prohibit the retail sale of disposable vaping devices nationwide, regardless of whether they contain nicotine.
  • Italy pointed out that Ireland's total ban constitutes a quantitative restriction, violating the Treaty on the Functioning of the European Union (TFEU) principle of free movement of goods.

 

2Firsts, April 10, 2026 

 

According to the European Commission, the EU's Technical Regulations Information System published a detailed opinion from Italy regarding Ireland's "Public Health (Single Use Vapes) Bill 2025." The bill originally planned to completely ban the retail sale of disposable vapes in Ireland.

 

Ban standstill period extended to June 2026

 

Under EU Directive 2015/1535, due to the submission of this detailed opinion by Italy, the standstill period for the Irish bill has been formally extended to June 19, 2026. During this period, Ireland may not adopt or implement the legislation.

 

Ireland notified the EU of the draft on December 18, 2025. The draft plans to completely ban the retail sale of any non-reusable vaping device, regardless of whether it contains nicotine. 

 

Italy's Ministry of Enterprises and Made in Italy submitted the formal objection to the European Commission on March 19, 2026.

 

Italy alleges ban violates EU principle of free movement of goods

 

In its detailed opinion, Italy explicitly stated that the Irish bill lacks scientific evidence and exceeds the existing EU regulatory framework. 

 

The ban constitutes a quantitative restriction under Article 34 of the Treaty on the Functioning of the European Union (TFEU), preventing products legally manufactured and sold in other EU member states from entering the Irish market, thereby violating the core principle of the free movement of goods.

 

At the same time, Italy argued that the measure is incompatible with Article 24 of the EU Tobacco Products Directive (2014/40/EU - TPD). 

 

The provision stipulates that member states can only ban specific categories of products under exceptional circumstances justified by the need to protect public health. Italy pointed out that Ireland failed to provide appropriate documentation proving the existence of such exceptional circumstances.

 

Lack of proportionality and alternative considerations

 

In its analysis of proportionality, Italy emphasised that Ireland's comprehensive ban failed to adequately assess less restrictive alternatives before restricting trade. 

 

For example, Ireland could have adopted stricter age control measures, targeted information campaigns, or differentiated taxation tools, rather than directly implementing a sales ban.

 

Furthermore, the ban was cited as undermining the "freedom of establishment" (Article 49 of TFEU) of legitimate EU operators already present or intending to operate in Ireland, raising risks of unequal treatment in market access and the fragmentation of EU regulations.

 

Image Source: European Commission

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Product | PMI Japan Launches SENTIA Passion Fruit Capsule, Expanding the IQOS ILUMA Flavor Portfolio
Product | PMI Japan Launches SENTIA Passion Fruit Capsule, Expanding the IQOS ILUMA Flavor Portfolio
Philip Morris Japan (PM Japan) has introduced SENTIA Passion Fruit Capsule, a new tobacco stick designed for the IQOS ILUMA heated tobacco platform. Featuring a crush-activated capsule, the product combines menthol with passion fruit flavor to provide an additional flavor experience. The product launched in Japan from August 3, 2026, through IQOS official channels, convenience stores and tobacco retailers.
Aug.04
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
The Philippines’ Bureau of Internal Revenue is intensifying enforcement against illicit vape and tobacco products ahead of the Christmas shopping season, directing regional and enforcement offices to strengthen monitoring of production sites, warehouses, distribution channels and retail outlets. The BIR destroyed 240,550 illicit vape products in August with an estimated tax liability of about PHP1.53 billion. A nationwide tax-compliance operation in July also inspected 3,590 businesses involved in tobacco and vapor products.
Regulations
Sep.17 by 2Firsts Perspectives
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
British American Tobacco (BAT) Global Travel Retail has expanded the VELO Travellers’ Collection with three new Summer Editions: Mexico, Spain and Sweden. Inspired by destination themes, the new nicotine pouch variants are designed for global travel-retail channels. The launch further strengthens VELO’s positioning as a travel-retail exclusive product collection.
Aug.27
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
AIR’s first half-year results as a listed company offer a new test of how far a traditional hookah business can transform. H1 2026 revenue rose 3.7%, even as Flavored Shisha Molasses shipments fell 9%, with pricing and mix supporting growth. Traditional shisha still generates almost all revenue, while OOKA, Crown Switch, Greentank and U.S. regulatory spending point to accelerating diversification. The next test is whether those investments can become a second business of meaningful scale and profitability.
Capital Markets
Aug.21